876 / 1851
Alternative drugs: CILENGITIDE (CENTRIC/EORTC 26071)
Cilengitide is a selective integrin inhibitor
Data from phase I-II studies suggest that it has antitumor activity
in association with TMZ (particularly in tumors with methylated
MGMT promoter).
545 patients randomized
to receive either CILENGITIDE
(272) or PLACEBO (273) in addition to Stupp regimen
Stupp R. et al. Lancet Oncol 2014;15
“The addition of Cilengitide to Stupp
regimen did not improve outcomes”